Combination Therapy for Advanced Acral Melanoma
Medical Supporter — Informationshinweis
Dieser Artikel ist eine Zusammenfassung internationaler medizinischer Informationen und stellt keine medizinische Beratung dar; er ersetzt nicht die Diagnose oder den Behandlungsplan Ihres behandelnden Arztes. Die dargestellten Informationen stammen aus öffentlichen Veröffentlichungen und offiziellen Angaben führender japanischer medizinischer Einrichtungen; Eignung und Wirkung einer Therapie sind individuell und müssen von einem qualifizierten Arzt beurteilt werden.
Combination Therapy for Advanced Acral Melanoma
- April 27, 2015
- Reading time: 2 minutes
On June 1, 2023, Dr. Lili Mao and colleagues from the Peking University Cancer Hospital and Institute published the results of a Phase 2 clinical trial in JAMA Oncology. The study evaluated the efficacy and safety of combining Camrelizumab (an anti-PD-1 antibody), Apatinib (a VEGFR-2 inhibitor), and Temozolomide (chemotherapy) as a first-line treatment for patients with untreated advanced acral melanoma.
Study Demographics: The trial enrolled 50 patients (64% male, N=32) with a median age of 57 years (range: 52–62). At a median follow-up of 13.4 months, the following clinical outcomes were reported:
Clinical Efficacy:
- Primary Endpoint (Objective Response Rate - ORR): 64.0%.
- Median Time to Response: 2.7 months.
- Median Duration of Response (DOR): 17.5 months.
- Disease Control Rate (DCR): 88.0%.
- Median Progression-Free Survival (PFS): 18.4 months.
- Median Overall Survival (OS): Not yet reached at the time of reporting.
Safety and Tolerability: Grade 3–4 adverse events included increased gamma-glutamyltransferase (30%), neutropenia (22%), increased blood bilirubin (20%), and increased aspartate aminotransferase (20%).
Conclusion: Based on the results of this Phase 2 trial, Dr. Lili Mao and the research team concluded that the combination of Camrelizumab, Apatinib, and Temozolomide demonstrated significant anti-tumor activity and a manageable safety profile. This combination has the potential to become a new standard of care for the first-line treatment of advanced acral melanoma.
Source: https://jamanetwork.com/journals/jamaoncology/article-abstract/2805681
Medical Supporter was formerly certified as a medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Behandlung in Japan im Blick? Brauchen Sie Informationen und Unterstützung?
Wir helfen Ihnen, die für eine medizinische Reise nach Japan nötigen Informationen zu ordnen, kontaktieren japanische Einrichtungen und organisieren eine Zweitmeinungsberatung.Die Erstberatung ist kostenlos; ein Berater hilft Ihnen, die nächsten Schritte zu klären.
Figure 1
Figure 2
Figure 3
Figure 4